INDIANAPOLIS, Indiana, August 12, 2026
Eli Lilly and Company has intensified its efforts to combat the illegal sale of retatrutide, filing six new lawsuits against U.S. entities accused of selling unapproved retatrutide products. The company is also calling on online platforms, payment companies, shipping providers, regulators, and law enforcement agencies to take stronger action against what it describes as a growing black market. Lilly said it has referred more than 200 individuals and entities to U.S. regulators and law enforcement and reported more than 14,000 websites, advertisements, social media posts, and product listings marketing retatrutide illegally across more than 100 countries. The company emphasized that retatrutide remains an investigational medicine and has not been approved for human use by any regulatory agency.
Lilly Files Six New Lawsuits Over Retatrutide
The latest legal action targets six U.S. entities that Lilly says are selling illegal retatrutide products, including compounding pharmacies, medical spas, and online sellers. The company alleges that some sellers falsely describe their products as being intended only for “research use” while marketing them for human consumption. Lilly is pursuing these actions as part of a broader effort to protect patients from products whose quality, safety, composition, and effectiveness have not been established through approved regulatory processes. The company has also referred hundreds of individuals and organizations to the U.S. Food and Drug Administration (FDA), U.S. Department of Justice, state attorneys general, law enforcement agencies, and professional licensing boards. Lilly said it is working with international regulators, customs authorities, and law enforcement organizations as well. According to the company, authorities in different countries have already taken enforcement actions involving illicit manufacturing operations and shipments associated with unapproved products.
Retatrutide Remains an Investigational Medicine
Retatrutide is currently being evaluated in Phase 3 clinical trials for obesity, type 2 diabetes, and related indications. Lilly stated that no medicine containing retatrutide has been approved for human use by any regulatory agency worldwide. The company therefore stressed that retatrutide cannot legally be marketed directly to consumers as an approved medicine. Lilly also cited FDA warnings concerning unapproved retatrutide products and so-called “research-use only” products, which may be of unknown quality and potentially harmful. The company said illicit sellers can market these products through online channels while presenting themselves as legitimate healthcare providers or wellness businesses. Lilly’s Chief Medical Officer, David A. Hyman, M.D., emphasized that the investigational drug is undergoing rigorous clinical evaluation and that products sold outside the regulated development process should not be considered equivalent to a tested and approved medicine.
Advertisement
Lilly Calls for Action Across Online and Payment Networks
Beyond litigation, Lilly is urging companies that provide infrastructure for online commerce to help disrupt the illegal retatrutide market. The company is asking social media and e-commerce platforms to proactively identify and remove unlawful listings and misleading promotional content. It is also calling on credit card companies, payment processors, shipping companies, and logistics providers to prevent their services from being used to facilitate the distribution of unapproved products. The company further urged healthcare providers to educate patients about the potential risks associated with unapproved retatrutide products and encouraged members of the public to report suspected illegal sales to appropriate regulatory and law enforcement authorities. Lilly said it has already reported thousands of websites, advertisements, social media posts, and product listings across international markets. The six newly filed lawsuits represent another escalation in Lilly’s effort to protect the integrity of its retatrutide clinical development program and patients considering obesity or diabetes treatments. While retatrutide continues to be investigated in controlled clinical studies, the company maintains that products sold through unauthorized channels have not undergone the same regulatory scrutiny. The distinction between an investigational drug undergoing clinical evaluation and unapproved products sold through the black market remains central to Lilly’s patient-safety campaign.
Source: Eli Lilly press release
